GeneDx Holdings (WGS) Capital Expenditures (2020 - 2026)

GeneDx Holdings has disclosed Capital Expenditures across 7 years of filings, most recently posting $5.9 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 169.23% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $10.0 million (up 129.92% YoY), while the FY2025 annual figure was $6.3 million, up 142.05% from the prior year.
• Capital Expenditures climbed to $5.9 million in Q1 2026, from -$8.4 million in the prior quarter.
• Over the last five years, Capital Expenditures for WGS reached as high as $8.9 million in Q3 2025 and fell as low as -$8.4 million in Q4 2025.
• The 5-year median for Capital Expenditures is $759000.0 (2023), against an average of $878352.9.
• The widest YoY moves for Capital Expenditures: up 6029.31% in 2025, down 5474.36% in 2025.
• A 5-year view of Capital Expenditures shows it stood at -$6.5 million in 2022, then jumped by 83.28% to -$1.1 million in 2023, then jumped by 114.36% to $156000.0 in 2024, then tumbled by 5474.36% to -$8.4 million in 2025, then surged by 170.55% to $5.9 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $5.9 million, -$8.4 million, and $8.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.